Skip to content

Study · Randomized controlled trial · n = 33 · 2017

4 results

Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.

Jørgensen PG, Jensen MT, Mensberg P, Storgaard H, Nyby S, Jensen JS, Knop FK, Vilsbøll T

Diabetes, obesity & metabolism20 Mar 2017Cited by 32 (Europe PMC)

PMID28188972 (opens in a new tab)DOI10.1111/dom.12900 (opens in a new tab)PepBankPUB-28188972
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes doing supervised exercise, early diastolic myocardial tissue velocity improved with placebo but not with liraglutide (between groups P = .02).

    In plain wordsIn adults with type 2 diabetes doing exercise, heart relaxation speed improved with placebo but not with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in early diastolic myocardial tissue velocity with exercise
    Study

    n = 33

    Comparator
    Placebo with supervised exercise
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (mean ± standard deviation [s.d.] -7.1 ± 1.6 to -7.7 ± 1.8 cm/s, P  = .01), but not in the liraglutide group (-7.1 ± 1.4 to -7.0 ± 1.4 cm/s, P  = .60; between groups, P  = .02).
    1 context sentence
    Summary · context
    We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes doing supervised exercise, the ratio of early and atrial mitral annular tissue velocities improved with placebo but not with liraglutide (between groups P = .03).

    In plain wordsIn adults with type 2 diabetes doing exercise, a measure of heart relaxation improved with placebo but not with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in ratio of early and atrial mitral annular tissue velocities with exercise
    Study

    n = 33

    Comparator
    Placebo with supervised exercise
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Similarly, the mean ± s.d. ratio of early and atrial mitral annular tissue velocities improved in the placebo group (1.0 ± 0.4 to 1.2 ± 0.4, P  = .003), but not in the liraglutide group (1.0 ± 0.3 to 1.0 ± 0.3, P  = .87; between groups, P  = .03).
    1 context sentence
    Summary · context
    We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes doing supervised exercise, heart rate did not differ significantly within or between the liraglutide and placebo groups.

    In plain wordsIn adults with type 2 diabetes doing exercise, heart rate did not change significantly with liraglutide compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeart rate
    Study

    n = 33

    Comparator
    Placebo with supervised exercise
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    We found no significant differences in heart rate, left ventricular (LV) structure or function within or between the groups.
    1 context sentence
    Summary · context
    We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes doing supervised exercise, left ventricular structure and function did not differ significantly within or between the liraglutide and placebo groups.

    In plain wordsIn adults with type 2 diabetes doing exercise, left heart chamber structure and function did not change significantly with liraglutide versus placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLeft ventricular structure and function
    Study

    n = 33

    Comparator
    Placebo with supervised exercise
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    We found no significant differences in heart rate, left ventricular (LV) structure or function within or between the groups.
    1 context sentence
    Summary · context
    We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo, combined with supervised exercise, in 33 dysregulated patients with type 2 diabetes on diet and/or metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.